Phase 2 N=132 AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism
Chronic Hypoparathyroidism
Primary: Treatment Emergent Adverse Events (TEAEs) — 2; 3; 5; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=13 Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations
Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Primary: Overall Response Rate — 5; 2; 3; 1 Participants
Phase 2 N=48 Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events
Submental Fat
Primary: Safety - Adverse Events Follow up — 1; 2; 3; 0 Participants
Phase 2 N=390 A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder
Borderline Personality Disorder
Primary: Change From Baseline in ZANarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) Total Score at Week 10 — -8.7; -8.0; -9.2; -8.9 units on a scale — p=0.4994
Phase 2 N=31 Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM
Glioblastoma Multiforme · Brain Tumor
Primary: Progression-free Survival (PFS) — 91.3 percentage of participants
Phase 2 N=14 The Effect of Minocycline and N-acetylcysteine for the Treatment of Fibromyalgia
Fibromyalgia
Primary: Change in Revised Fibromyalgia Impact Questionnaire (FIQR) Score From Baseline to After Treatment Occurring at Weeks 8 and 18 — 4.37; 12.1 Score
Phase 2 N=235 Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma
Asthma
Primary: Change From Baseline to Week 16 in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in the First Second (FEV1) as Measured in the Study Clinic — 0.148; 0.116; 0.112…
Phase 2 N=105 IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
Squamous Cell Carcinoma of the Oral Cavity
Primary: Event-free Survival (EFS)- Number of Participants With an Event — 31; 15 Participants
Phase 2 N=20 Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone
Prostate Cancer Metastatic to Bone
Primary: Count of Participants Requiring Androgen Deprivation Therapy (ADT) Use at 15 Months — 10 Participants
Phase 2 N=14 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
Prostate Cancer
Primary: Number of Participants for Which an Assessment of PET Based Therapeutic Response to HIFU is Successfully Obtained — 14; 14 Participants
Phase 2 N=20 "Follow the Sutures". A New Procedure for Injection of Botulinum Toxin for Chronic Migraine
Migraine Disorders · Chronic Disease
Primary: Number of Adverse Events — 1 Participants
Phase 2 N=152 Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in…
Phase 2 N=65 Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)
Cytomegalovirus (CMV) Infection
Primary: Area Under the Concentration-time Curve From Time 0 to 24 Hours Post-dose (AUC0-24) of Plasma Letermovir Taken as Oral Formulation by Ages 2 - <18 Years — 80300; 62900…
Phase 2 N=27 Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer
Prostate Adenocarcinoma · PSA Progression · Recurrent Prostate Carcinoma
Primary: Number of Lesions Detected by Investigational Imaging Agent — 31; 20 lesions
Phase 2 N=56 Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
Metastatic Castration Resistant Prostate Cancer · Metastatic Cancer · Solid Tumor
Primary: The Proportion of Patients With CDK12 Loss of Function Metastatic CRPC That Respond to Treatment. — 2; 0 participants